Study of iStent Trabecular Micro-Bypass Stent in glaucoma published in Journal of Cataract and Refractive Surgery- Glaukos Corp

Glaukos Corporation has announced that a new clinical study, published in the Journal of Cataract and Refractive Surgery, showed use of the iStent Trabecular Micro-Bypass Stent in conjunction with cataract surgery provided a 36% reduction in mean intraocular pressure (IOP) and an 86% reduction in the mean number of glaucoma medications three years following surgery. In 39 eyes followed through three years, the mean IOP at three years was 14.9 mmHg, compared to a mean preoperative IOP of 23.4 mmHg. In the same 39 eyes, the mean number of glaucoma medications used three years following surgery declined to 0.3, compared to a mean of 1.9 medications at subjects' preoperative visits.

No operative complications occurred during the cataract surgical procedure or during the stent implantation procedure. Over the three-year follow-up period, five secondary surgeries, two postoperative ocular sequelae and two non-ocular adverse events were reported. The prospective, open-label, non-randomized study was conducted at the Eye Clinic Marienplatz in Munich, Germany by Medical Director Tobias H. Neuhann.